RS65379B1 - (+)-azasetron za upotrebu u lečenju poremećaja uha - Google Patents

(+)-azasetron za upotrebu u lečenju poremećaja uha

Info

Publication number
RS65379B1
RS65379B1 RS20240412A RSP20240412A RS65379B1 RS 65379 B1 RS65379 B1 RS 65379B1 RS 20240412 A RS20240412 A RS 20240412A RS P20240412 A RSP20240412 A RS P20240412A RS 65379 B1 RS65379 B1 RS 65379B1
Authority
RS
Serbia
Prior art keywords
azasetron
composition
exemplary embodiment
ear
hearing loss
Prior art date
Application number
RS20240412A
Other languages
English (en)
Serbian (sr)
Inventor
Jonas Dyhrfjeld-Johnsen
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Priority claimed from EP17717441.4A external-priority patent/EP3442537B1/en
Publication of RS65379B1 publication Critical patent/RS65379B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20240412A 2016-04-14 2017-04-14 (+)-azasetron za upotrebu u lečenju poremećaja uha RS65379B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662322690P 2016-04-14 2016-04-14
EP16180192 2016-07-19
EP17717441.4A EP3442537B1 (en) 2016-04-14 2017-04-14 (+)-azasetron for use in the treatment of ear disorders
PCT/EP2017/059058 WO2017178645A1 (en) 2016-04-14 2017-04-14 (+)-azasetron for use in the treatment of ear disorders

Publications (1)

Publication Number Publication Date
RS65379B1 true RS65379B1 (sr) 2024-04-30

Family

ID=65588799

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240412A RS65379B1 (sr) 2016-04-14 2017-04-14 (+)-azasetron za upotrebu u lečenju poremećaja uha

Country Status (18)

Country Link
US (2) US11612605B2 (https=)
EP (1) EP4335508A3 (https=)
JP (1) JP7158723B2 (https=)
CN (1) CN109310698B (https=)
AU (1) AU2023202897B2 (https=)
CL (1) CL2018002930A1 (https=)
DK (1) DK3442537T3 (https=)
ES (1) ES2975016T3 (https=)
FI (1) FI3442537T3 (https=)
HR (1) HRP20240453T1 (https=)
HU (1) HUE066000T2 (https=)
IL (1) IL262305B (https=)
MX (1) MX384045B (https=)
NZ (1) NZ747201A (https=)
PL (1) PL3442537T3 (https=)
RS (1) RS65379B1 (https=)
SI (1) SI3442537T1 (https=)
ZA (1) ZA201806894B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2882602T3 (es) * 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
GB0104554D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New uses
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
GB0213869D0 (en) 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
NZ541009A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040204466A1 (en) 2003-04-14 2004-10-14 Orchid Chemicals And Pharmaceuticals Ltd. Treatment of bronchial asthma using 5-HT3 receptor antagonists
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US20100016218A1 (en) 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
CN102458400B (zh) 2009-05-20 2014-10-08 国立健康与医学研究所 用于治疗病灶性前庭功能障碍的血清素5-ht3受体拮抗剂
CN101786963B (zh) 2010-03-03 2013-05-08 山东众诚药业股份有限公司 阿扎司琼中间体的合成方法
JP2015511242A (ja) 2012-02-23 2015-04-16 インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル) 病変性前庭障害の治療に使用するカルシニューリン阻害剤
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
BR112016002205A2 (pt) * 2013-07-31 2017-08-01 Bluepharma Ind Farmaceutica S A filmes orodispersíveis
CN104557906A (zh) 2015-01-21 2015-04-29 扬子江药业集团四川海蓉药业有限公司 一种盐酸阿扎司琼的制备方法
ES2882602T3 (es) * 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva

Also Published As

Publication number Publication date
DK3442537T3 (da) 2024-03-25
EP4335508A3 (en) 2024-07-10
US20230226071A1 (en) 2023-07-20
NZ747201A (en) 2023-02-24
JP7158723B2 (ja) 2022-10-24
US20190083503A1 (en) 2019-03-21
JP2019513780A (ja) 2019-05-30
EP4335508A2 (en) 2024-03-13
FI3442537T3 (fi) 2024-04-04
IL262305B (en) 2022-03-01
HUE066000T2 (hu) 2024-06-28
US11612605B2 (en) 2023-03-28
IL262305A (en) 2018-11-29
HRP20240453T1 (hr) 2024-06-21
MX2018012587A (es) 2019-03-07
AU2023202897B2 (en) 2025-01-30
CL2018002930A1 (es) 2019-02-15
ES2975016T3 (es) 2024-07-02
SI3442537T1 (sl) 2024-05-31
CN109310698B (zh) 2021-12-24
MX384045B (es) 2025-03-14
PL3442537T3 (pl) 2024-07-15
ZA201806894B (en) 2023-03-29
AU2023202897A1 (en) 2023-05-25
CN109310698A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
EP2203050B1 (en) Topical use of r(+)-n-propargyl-1-aminoindan to treat or prevent hearing loss
JP5612473B2 (ja) 難聴を処置又は予防するための1−アミノ−アルキルシクロヘキサン誘導体
EP3442537B1 (en) (+)-azasetron for use in the treatment of ear disorders
CN107735091B (zh) 包含伊马替尼作为活性成分的用于预防和治疗干眼病的药物组合物
AU2023202897B2 (en) (+)-Azasetron for use in the treatment of ear disorders
JP6271804B1 (ja) 耳炎の治療のための組成物および方法
HK40106593A (en) (+)-azasetron for use in the treatment of ear disorders
CN110664765B (zh) 一种倍他司汀舌下含片及其制备方法和用途
EP4452267B1 (en) 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases
HK40003071B (en) (+)-azasetron for use in the treatment of ear disorders
HK40003071A (en) (+)-azasetron for use in the treatment of ear disorders
JP7837967B2 (ja) 抗眩暈組成物及びその医薬組成物
BR112018071123B1 (pt) (+)-azasetron para uso no tratamento de distúrbios de ouvido
WO2021127275A1 (en) Gsk-3 modulator otic formulations
US20220265668A1 (en) Treatment and/or prevention of lesions in the central auditory nervous system
WO2026062170A1 (en) Azasetron for the prevention of hearing loss in subjects receiving cisplatin
KR20260033532A (ko) 인공와우 이식 후 잔여 청력의 보존을 위한 아자세트론
RU2452476C2 (ru) Производные 1-аминоалкилциклогексана для лечения и предупреждения потери слуха
CN119136809A (zh) 阿扎司琼用于治疗突发性感音神经性听力损失
Ismail Vertigo. A neurobiological review
HK1145419B (en) Topical use of r(+)-n-propargyl-1-aminoindan to treat or prevent hearing loss